The global Selective Cox-2 Inhibitors market size was valued at US$ 5.67 billion in 2024 and is projected to reach US$ 7.22 billion by 2030, at a CAGR of 4.1% during the forecast period 2024-2030.
United States Selective Cox-2 Inhibitors market size was valued at US$ 1.85 billion in 2024 and is projected to reach US$ 2.27 billion by 2030, at a CAGR of 3.5% during the forecast period 2024-2030.
Non-steroidal anti-inflammatory drugs that selectively inhibit cyclooxygenase-2 enzyme.
Moderate growth driven by ongoing demand in pain management and arthritis treatment. Concerns over cardiovascular risks limiting market expansion. Development of new formulations and combination therapies to improve safety profiles.
Report Overview
This report provides a deep insight into the global Selective Cox-2 Inhibitors market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Selective Cox-2 Inhibitors Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Selective Cox-2 Inhibitors market in any manner.
Global Selective Cox-2 Inhibitors Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
- Boehringer-Ingelheim
- TerSera Therapeutics
- Iroko Pharmaceuticals
- Apotex
- Yung Shin Pharmaceutical
- Breckenridge Pharmaceutical
- Meda Pharmaceuticals
- Cipla
- Glenmark Pharmaceuticals
- Teva
- PuraCap Pharmaceutical
- Almirall Limited
- Lupin Pharmaceuticals
- Aurobindo Pharma
- Pfizer
- Mylan
- Takeda
- Bayer
- Novacap
- Abbott
- Geri-Care
- Perrigo
- Kopran
- Merck
- Hengrui pharmaceutical
- Kelun Group
- Qilu Pharmaceutical
- Taro Pharmaceuticals
Market Segmentation (by Type)
- Meloxicam
- Celecoxib
- Etoricoxib
- Imrecoxib
- Etodolac
- Parecoxib
- Other
Market Segmentation (by Application)
- Rheumatoid Arthritis
- Osteoarthritis
- Spondylosis Chronica Ankylopoietica
- Other
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Selective Cox-2 Inhibitors Market
- Overview of the regional outlook of the Selective Cox-2 Inhibitors Market:
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value (USD Billion) data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the
major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Selective Cox-2 Inhibitors
1.2 Key Market Segments
1.2.1 Selective Cox-2 Inhibitors Segment by Type
1.2.2 Selective Cox-2 Inhibitors Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Selective Cox-2 Inhibitors Market Overview
2.1 Global Market Overview
2.1.1 Global Selective Cox-2 Inhibitors Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Selective Cox-2 Inhibitors Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Selective Cox-2 Inhibitors Market Competitive Landscape
3.1 Global Selective Cox-2 Inhibitors Sales by Manufacturers (2019-2024)
3.2 Global Selective Cox-2 Inhibitors Revenue Market Share by Manufacturers (2019-2024)
3.3 Selective Cox-2 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Selective Cox-2 Inhibitors Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Selective Cox-2 Inhibitors Sales Sites, Area Served, Product Type
3.6 Selective Cox-2 Inhibitors Market Competitive Situation and Trends
3.6.1 Selective Cox-2 Inhibitors Market Concentration Rate
3.6.2 Global 5 and 10 Largest Selective Cox-2 Inhibitors Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Selective Cox-2 Inhibitors Industry Chain Analysis
4.1 Selective Cox-2 Inhibitors Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Selective Cox-2 Inhibitors Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Selective Cox-2 Inhibitors Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Selective Cox-2 Inhibitors Sales Market Share by Type (2019-2024)
6.3 Global Selective Cox-2 Inhibitors Market Size Market Share by Type (2019-2024)
6.4 Global Selective Cox-2 Inhibitors Price by Type (2019-2024)
7 Selective Cox-2 Inhibitors Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Selective Cox-2 Inhibitors Market Sales by Application (2019-2024)
7.3 Global Selective Cox-2 Inhibitors Market Size (M USD) by Application (2019-2024)
7.4 Global Selective Cox-2 Inhibitors Sales Growth Rate by Application (2019-2024)
8 Selective Cox-2 Inhibitors Market Segmentation by Region
8.1 Global Selective Cox-2 Inhibitors Sales by Region
8.1.1 Global Selective Cox-2 Inhibitors Sales by Region
8.1.2 Global Selective Cox-2 Inhibitors Sales Market Share by Region
8.2 North America
8.2.1 North America Selective Cox-2 Inhibitors Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Selective Cox-2 Inhibitors Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Selective Cox-2 Inhibitors Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Selective Cox-2 Inhibitors Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Selective Cox-2 Inhibitors Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Boehringer-Ingelheim
9.1.1 Boehringer-Ingelheim Selective Cox-2 Inhibitors Basic Information
9.1.2 Boehringer-Ingelheim Selective Cox-2 Inhibitors Product Overview
9.1.3 Boehringer-Ingelheim Selective Cox-2 Inhibitors Product Market Performance
9.1.4 Boehringer-Ingelheim Business Overview
9.1.5 Boehringer-Ingelheim Selective Cox-2 Inhibitors SWOT Analysis
9.1.6 Boehringer-Ingelheim Recent Developments
9.2 TerSera Therapeutics
9.2.1 TerSera Therapeutics Selective Cox-2 Inhibitors Basic Information
9.2.2 TerSera Therapeutics Selective Cox-2 Inhibitors Product Overview
9.2.3 TerSera Therapeutics Selective Cox-2 Inhibitors Product Market Performance
9.2.4 TerSera Therapeutics Business Overview
9.2.5 TerSera Therapeutics Selective Cox-2 Inhibitors SWOT Analysis
9.2.6 TerSera Therapeutics Recent Developments
9.3 Iroko Pharmaceuticals
9.3.1 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Basic Information
9.3.2 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Product Overview
9.3.3 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Product Market Performance
9.3.4 Iroko Pharmaceuticals Selective Cox-2 Inhibitors SWOT Analysis
9.3.5 Iroko Pharmaceuticals Business Overview
9.3.6 Iroko Pharmaceuticals Recent Developments
9.4 Apotex
9.4.1 Apotex Selective Cox-2 Inhibitors Basic Information
9.4.2 Apotex Selective Cox-2 Inhibitors Product Overview
9.4.3 Apotex Selective Cox-2 Inhibitors Product Market Performance
9.4.4 Apotex Business Overview
9.4.5 Apotex Recent Developments
9.5 Yung Shin Pharmaceutical
9.5.1 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Basic Information
9.5.2 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Product Overview
9.5.3 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Product Market Performance
9.5.4 Yung Shin Pharmaceutical Business Overview
9.5.5 Yung Shin Pharmaceutical Recent Developments
9.6 Breckenridge Pharmaceutical
9.6.1 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Basic Information
9.6.2 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Product Overview
9.6.3 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Product Market Performance
9.6.4 Breckenridge Pharmaceutical Business Overview
9.6.5 Breckenridge Pharmaceutical Recent Developments
9.7 Meda Pharmaceuticals
9.7.1 Meda Pharmaceuticals Selective Cox-2 Inhibitors Basic Information
9.7.2 Meda Pharmaceuticals Selective Cox-2 Inhibitors Product Overview
9.7.3 Meda Pharmaceuticals Selective Cox-2 Inhibitors Product Market Performance
9.7.4 Meda Pharmaceuticals Business Overview
9.7.5 Meda Pharmaceuticals Recent Developments
9.8 Cipla
9.8.1 Cipla Selective Cox-2 Inhibitors Basic Information
9.8.2 Cipla Selective Cox-2 Inhibitors Product Overview
9.8.3 Cipla Selective Cox-2 Inhibitors Product Market Performance
9.8.4 Cipla Business Overview
9.8.5 Cipla Recent Developments
9.9 Glenmark Pharmaceuticals
9.9.1 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Basic Information
9.9.2 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Product Overview
9.9.3 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Product Market Performance
9.9.4 Glenmark Pharmaceuticals Business Overview
9.9.5 Glenmark Pharmaceuticals Recent Developments
9.10 Teva
9.10.1 Teva Selective Cox-2 Inhibitors Basic Information
9.10.2 Teva Selective Cox-2 Inhibitors Product Overview
9.10.3 Teva Selective Cox-2 Inhibitors Product Market Performance
9.10.4 Teva Business Overview
9.10.5 Teva Recent Developments
9.11 PuraCap Pharmaceutical
9.11.1 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Basic Information
9.11.2 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Product Overview
9.11.3 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Product Market Performance
9.11.4 PuraCap Pharmaceutical Business Overview
9.11.5 PuraCap Pharmaceutical Recent Developments
9.12 Almirall Limited
9.12.1 Almirall Limited Selective Cox-2 Inhibitors Basic Information
9.12.2 Almirall Limited Selective Cox-2 Inhibitors Product Overview
9.12.3 Almirall Limited Selective Cox-2 Inhibitors Product Market Performance
9.12.4 Almirall Limited Business Overview
9.12.5 Almirall Limited Recent Developments
9.13 Lupin Pharmaceuticals
9.13.1 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Basic Information
9.13.2 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Product Overview
9.13.3 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Product Market Performance
9.13.4 Lupin Pharmaceuticals Business Overview
9.13.5 Lupin Pharmaceuticals Recent Developments
9.14 Aurobindo Pharma
9.14.1 Aurobindo Pharma Selective Cox-2 Inhibitors Basic Information
9.14.2 Aurobindo Pharma Selective Cox-2 Inhibitors Product Overview
9.14.3 Aurobindo Pharma Selective Cox-2 Inhibitors Product Market Performance
9.14.4 Aurobindo Pharma Business Overview
9.14.5 Aurobindo Pharma Recent Developments
9.15 Pfizer
9.15.1 Pfizer Selective Cox-2 Inhibitors Basic Information
9.15.2 Pfizer Selective Cox-2 Inhibitors Product Overview
9.15.3 Pfizer Selective Cox-2 Inhibitors Product Market Performance
9.15.4 Pfizer Business Overview
9.15.5 Pfizer Recent Developments
9.16 Mylan
9.16.1 Mylan Selective Cox-2 Inhibitors Basic Information
9.16.2 Mylan Selective Cox-2 Inhibitors Product Overview
9.16.3 Mylan Selective Cox-2 Inhibitors Product Market Performance
9.16.4 Mylan Business Overview
9.16.5 Mylan Recent Developments
9.17 Takeda
9.17.1 Takeda Selective Cox-2 Inhibitors Basic Information
9.17.2 Takeda Selective Cox-2 Inhibitors Product Overview
9.17.3 Takeda Selective Cox-2 Inhibitors Product Market Performance
9.17.4 Takeda Business Overview
9.17.5 Takeda Recent Developments
9.18 Bayer
9.18.1 Bayer Selective Cox-2 Inhibitors Basic Information
9.18.2 Bayer Selective Cox-2 Inhibitors Product Overview
9.18.3 Bayer Selective Cox-2 Inhibitors Product Market Performance
9.18.4 Bayer Business Overview
9.18.5 Bayer Recent Developments
9.19 Novacap
9.19.1 Novacap Selective Cox-2 Inhibitors Basic Information
9.19.2 Novacap Selective Cox-2 Inhibitors Product Overview
9.19.3 Novacap Selective Cox-2 Inhibitors Product Market Performance
9.19.4 Novacap Business Overview
9.19.5 Novacap Recent Developments
9.20 Abbott
9.20.1 Abbott Selective Cox-2 Inhibitors Basic Information
9.20.2 Abbott Selective Cox-2 Inhibitors Product Overview
9.20.3 Abbott Selective Cox-2 Inhibitors Product Market Performance
9.20.4 Abbott Business Overview
9.20.5 Abbott Recent Developments
9.21 Geri-Care
9.21.1 Geri-Care Selective Cox-2 Inhibitors Basic Information
9.21.2 Geri-Care Selective Cox-2 Inhibitors Product Overview
9.21.3 Geri-Care Selective Cox-2 Inhibitors Product Market Performance
9.21.4 Geri-Care Business Overview
9.21.5 Geri-Care Recent Developments
9.22 Perrigo
9.22.1 Perrigo Selective Cox-2 Inhibitors Basic Information
9.22.2 Perrigo Selective Cox-2 Inhibitors Product Overview
9.22.3 Perrigo Selective Cox-2 Inhibitors Product Market Performance
9.22.4 Perrigo Business Overview
9.22.5 Perrigo Recent Developments
9.23 Kopran
9.23.1 Kopran Selective Cox-2 Inhibitors Basic Information
9.23.2 Kopran Selective Cox-2 Inhibitors Product Overview
9.23.3 Kopran Selective Cox-2 Inhibitors Product Market Performance
9.23.4 Kopran Business Overview
9.23.5 Kopran Recent Developments
9.24 Merck
9.24.1 Merck Selective Cox-2 Inhibitors Basic Information
9.24.2 Merck Selective Cox-2 Inhibitors Product Overview
9.24.3 Merck Selective Cox-2 Inhibitors Product Market Performance
9.24.4 Merck Business Overview
9.24.5 Merck Recent Developments
9.25 Hengrui pharmaceutical
9.25.1 Hengrui pharmaceutical Selective Cox-2 Inhibitors Basic Information
9.25.2 Hengrui pharmaceutical Selective Cox-2 Inhibitors Product Overview
9.25.3 Hengrui pharmaceutical Selective Cox-2 Inhibitors Product Market Performance
9.25.4 Hengrui pharmaceutical Business Overview
9.25.5 Hengrui pharmaceutical Recent Developments
9.26 Kelun Group
9.26.1 Kelun Group Selective Cox-2 Inhibitors Basic Information
9.26.2 Kelun Group Selective Cox-2 Inhibitors Product Overview
9.26.3 Kelun Group Selective Cox-2 Inhibitors Product Market Performance
9.26.4 Kelun Group Business Overview
9.26.5 Kelun Group Recent Developments
9.27 Qilu Pharmaceutical
9.27.1 Qilu Pharmaceutical Selective Cox-2 Inhibitors Basic Information
9.27.2 Qilu Pharmaceutical Selective Cox-2 Inhibitors Product Overview
9.27.3 Qilu Pharmaceutical Selective Cox-2 Inhibitors Product Market Performance
9.27.4 Qilu Pharmaceutical Business Overview
9.27.5 Qilu Pharmaceutical Recent Developments
9.28 Taro Pharmaceuticals
9.28.1 Taro Pharmaceuticals Selective Cox-2 Inhibitors Basic Information
9.28.2 Taro Pharmaceuticals Selective Cox-2 Inhibitors Product Overview
9.28.3 Taro Pharmaceuticals Selective Cox-2 Inhibitors Product Market Performance
9.28.4 Taro Pharmaceuticals Business Overview
9.28.5 Taro Pharmaceuticals Recent Developments
10 Selective Cox-2 Inhibitors Market Forecast by Region
10.1 Global Selective Cox-2 Inhibitors Market Size Forecast
10.2 Global Selective Cox-2 Inhibitors Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Selective Cox-2 Inhibitors Market Size Forecast by Country
10.2.3 Asia Pacific Selective Cox-2 Inhibitors Market Size Forecast by Region
10.2.4 South America Selective Cox-2 Inhibitors Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Selective Cox-2 Inhibitors by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Selective Cox-2 Inhibitors Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Selective Cox-2 Inhibitors by Type (2025-2030)
11.1.2 Global Selective Cox-2 Inhibitors Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Selective Cox-2 Inhibitors by Type (2025-2030)
11.2 Global Selective Cox-2 Inhibitors Market Forecast by Application (2025-2030)
11.2.1 Global Selective Cox-2 Inhibitors Sales (K Units) Forecast by Application
11.2.2 Global Selective Cox-2 Inhibitors Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Selective Cox-2 Inhibitors Market Size Comparison by Region (M USD)
Table 5. Global Selective Cox-2 Inhibitors Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Selective Cox-2 Inhibitors Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Selective Cox-2 Inhibitors Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Selective Cox-2 Inhibitors Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Selective Cox-2 Inhibitors as of 2022)
Table 10. Global Market Selective Cox-2 Inhibitors Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Selective Cox-2 Inhibitors Sales Sites and Area Served
Table 12. Manufacturers Selective Cox-2 Inhibitors Product Type
Table 13. Global Selective Cox-2 Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Selective Cox-2 Inhibitors
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Selective Cox-2 Inhibitors Market Challenges
Table 22. Global Selective Cox-2 Inhibitors Sales by Type (K Units)
Table 23. Global Selective Cox-2 Inhibitors Market Size by Type (M USD)
Table 24. Global Selective Cox-2 Inhibitors Sales (K Units) by Type (2019-2024)
Table 25. Global Selective Cox-2 Inhibitors Sales Market Share by Type (2019-2024)
Table 26. Global Selective Cox-2 Inhibitors Market Size (M USD) by Type (2019-2024)
Table 27. Global Selective Cox-2 Inhibitors Market Size Share by Type (2019-2024)
Table 28. Global Selective Cox-2 Inhibitors Price (USD/Unit) by Type (2019-2024)
Table 29. Global Selective Cox-2 Inhibitors Sales (K Units) by Application
Table 30. Global Selective Cox-2 Inhibitors Market Size by Application
Table 31. Global Selective Cox-2 Inhibitors Sales by Application (2019-2024) & (K Units)
Table 32. Global Selective Cox-2 Inhibitors Sales Market Share by Application (2019-2024)
Table 33. Global Selective Cox-2 Inhibitors Sales by Application (2019-2024) & (M USD)
Table 34. Global Selective Cox-2 Inhibitors Market Share by Application (2019-2024)
Table 35. Global Selective Cox-2 Inhibitors Sales Growth Rate by Application (2019-2024)
Table 36. Global Selective Cox-2 Inhibitors Sales by Region (2019-2024) & (K Units)
Table 37. Global Selective Cox-2 Inhibitors Sales Market Share by Region (2019-2024)
Table 38. North America Selective Cox-2 Inhibitors Sales by Country (2019-2024) & (K Units)
Table 39. Europe Selective Cox-2 Inhibitors Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Selective Cox-2 Inhibitors Sales by Region (2019-2024) & (K Units)
Table 41. South America Selective Cox-2 Inhibitors Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Selective Cox-2 Inhibitors Sales by Region (2019-2024) & (K Units)
Table 43. Boehringer-Ingelheim Selective Cox-2 Inhibitors Basic Information
Table 44. Boehringer-Ingelheim Selective Cox-2 Inhibitors Product Overview
Table 45. Boehringer-Ingelheim Selective Cox-2 Inhibitors Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Boehringer-Ingelheim Business Overview
Table 47. Boehringer-Ingelheim Selective Cox-2 Inhibitors SWOT Analysis
Table 48. Boehringer-Ingelheim Recent Developments
Table 49. TerSera Therapeutics Selective Cox-2 Inhibitors Basic Information
Table 50. TerSera Therapeutics Selective Cox-2 Inhibitors Product Overview
Table 51. TerSera Therapeutics Selective Cox-2 Inhibitors Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. TerSera Therapeutics Business Overview
Table 53. TerSera Therapeutics Selective Cox-2 Inhibitors SWOT Analysis
Table 54. TerSera Therapeutics Recent Developments
Table 55. Iroko Pharmaceuticals Selective Cox-2 Inhibitors Basic Information
Table 56. Iroko Pharmaceuticals Selective Cox-2 Inhibitors Product Overview
Table 57. Iroko Pharmaceuticals Selective Cox-2 Inhibitors Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Iroko Pharmaceuticals Selective Cox-2 Inhibitors SWOT Analysis
Table 59. Iroko Pharmaceuticals Business Overview
Table 60. Iroko Pharmaceuticals Recent Developments
Table 61. Apotex Selective Cox-2 Inhibitors Basic Information
Table 62. Apotex Selective Cox-2 Inhibitors Product Overview
Table 63. Apotex Selective Cox-2 Inhibitors Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Apotex Business Overview
Table 65. Apotex Recent Developments
Table 66. Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Basic Information
Table 67. Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Product Overview
Table 68. Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Yung Shin Pharmaceutical Business Overview
Table 70. Yung Shin Pharmaceutical Recent Developments
Table 71. Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Basic Information
Table 72. Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Product Overview
Table 73. Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Breckenridge Pharmaceutical Business Overview
Table 75. Breckenridge Pharmaceutical Recent Developments
Table 76. Meda Pharmaceuticals Selective Cox-2 Inhibitors Basic Information
Table 77. Meda Pharmaceuticals Selective Cox-2 Inhibitors Product Overview
Table 78. Meda Pharmaceuticals Selective Cox-2 Inhibitors Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Meda Pharmaceuticals Business Overview
Table 80. Meda Pharmaceuticals Recent Developments
Table 81. Cipla Selective Cox-2 Inhibitors Basic Information
Table 82. Cipla Selective Cox-2 Inhibitors Product Overview
Table 83. Cipla Selective Cox-2 Inhibitors Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Cipla Business Overview
Table 85. Cipla Recent Developments
Table 86. Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Basic Information
Table 87. Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Product Overview
Table 88. Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Glenmark Pharmaceuticals Business Overview
Table 90. Glenmark Pharmaceuticals Recent Developments
Table 91. Teva Selective Cox-2 Inhibitors Basic Information
Table 92. Teva Selective Cox-2 Inhibitors Product Overview
Table 93. Teva Selective Cox-2 Inhibitors Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Teva Business Overview
Table 95. Teva Recent Developments
Table 96. PuraCap Pharmaceutical Selective Cox-2 Inhibitors Basic Information
Table 97. PuraCap Pharmaceutical Selective Cox-2 Inhibitors Product Overview
Table 98. PuraCap Pharmaceutical Selective Cox-2 Inhibitors Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. PuraCap Pharmaceutical Business Overview
Table 100. PuraCap Pharmaceutical Recent Developments
Table 101. Almirall Limited Selective Cox-2 Inhibitors Basic Information
Table 102. Almirall Limited Selective Cox-2 Inhibitors Product Overview
Table 103. Almirall Limited Selective Cox-2 Inhibitors Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. Almirall Limited Business Overview
Table 105. Almirall Limited Recent Developments
Table 106. Lupin Pharmaceuticals Selective Cox-2 Inhibitors Basic Information
Table 107. Lupin Pharmaceuticals Selective Cox-2 Inhibitors Product Overview
Table 108. Lupin Pharmaceuticals Selective Cox-2 Inhibitors Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. Lupin Pharmaceuticals Business Overview
Table 110. Lupin Pharmaceuticals Recent Developments
Table 111. Aurobindo Pharma Selective Cox-2 Inhibitors Basic Information
Table 112. Aurobindo Pharma Selective Cox-2 Inhibitors Product Overview
Table 113. Aurobindo Pharma Selective Cox-2 Inhibitors Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 114. Aurobindo Pharma Business Overview
Table 115. Aurobindo Pharma Recent Developments
Table 116. Pfizer Selective Cox-2 Inhibitors Basic Information
Table 117. Pfizer Selective Cox-2 Inhibitors Product Overview
Table 118. Pfizer Selective Cox-2 Inhibitors Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 119. Pfizer Business Overview
Table 120. Pfizer Recent Developments
Table 121. Mylan Selective Cox-2 Inhibitors Basic Information
Table 122. Mylan Selective Cox-2 Inhibitors Product Overview
Table 123. Mylan Selective Cox-2 Inhibitors Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 124. Mylan Business Overview
Table 125. Mylan Recent Developments
Table 126. Takeda Selective Cox-2 Inhibitors Basic Information
Table 127. Takeda Selective Cox-2 Inhibitors Product Overview
Table 128. Takeda Selective Cox-2 Inhibitors Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 129. Takeda Business Overview
Table 130. Takeda Recent Developments
Table 131. Bayer Selective Cox-2 Inhibitors Basic Information
Table 132. Bayer Selective Cox-2 Inhibitors Product Overview
Table 133. Bayer Selective Cox-2 Inhibitors Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 134. Bayer Business Overview
Table 135. Bayer Recent Developments
Table 136. Novacap Selective Cox-2 Inhibitors Basic Information
Table 137. Novacap Selective Cox-2 Inhibitors Product Overview
Table 138. Novacap Selective Cox-2 Inhibitors Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 139. Novacap Business Overview
Table 140. Novacap Recent Developments
Table 141. Abbott Selective Cox-2 Inhibitors Basic Information
Table 142. Abbott Selective Cox-2 Inhibitors Product Overview
Table 143. Abbott Selective Cox-2 Inhibitors Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 144. Abbott Business Overview
Table 145. Abbott Recent Developments
Table 146. Geri-Care Selective Cox-2 Inhibitors Basic Information
Table 147. Geri-Care Selective Cox-2 Inhibitors Product Overview
Table 148. Geri-Care Selective Cox-2 Inhibitors Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 149. Geri-Care Business Overview
Table 150. Geri-Care Recent Developments
Table 151. Perrigo Selective Cox-2 Inhibitors Basic Information
Table 152. Perrigo Selective Cox-2 Inhibitors Product Overview
Table 153. Perrigo Selective Cox-2 Inhibitors Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 154. Perrigo Business Overview
Table 155. Perrigo Recent Developments
Table 156. Kopran Selective Cox-2 Inhibitors Basic Information
Table 157. Kopran Selective Cox-2 Inhibitors Product Overview
Table 158. Kopran Selective Cox-2 Inhibitors Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 159. Kopran Business Overview
Table 160. Kopran Recent Developments
Table 161. Merck Selective Cox-2 Inhibitors Basic Information
Table 162. Merck Selective Cox-2 Inhibitors Product Overview
Table 163. Merck Selective Cox-2 Inhibitors Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 164. Merck Business Overview
Table 165. Merck Recent Developments
Table 166. Hengrui pharmaceutical Selective Cox-2 Inhibitors Basic Information
Table 167. Hengrui pharmaceutical Selective Cox-2 Inhibitors Product Overview
Table 168. Hengrui pharmaceutical Selective Cox-2 Inhibitors Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 169. Hengrui pharmaceutical Business Overview
Table 170. Hengrui pharmaceutical Recent Developments
Table 171. Kelun Group Selective Cox-2 Inhibitors Basic Information
Table 172. Kelun Group Selective Cox-2 Inhibitors Product Overview
Table 173. Kelun Group Selective Cox-2 Inhibitors Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 174. Kelun Group Business Overview
Table 175. Kelun Group Recent Developments
Table 176. Qilu Pharmaceutical Selective Cox-2 Inhibitors Basic Information
Table 177. Qilu Pharmaceutical Selective Cox-2 Inhibitors Product Overview
Table 178. Qilu Pharmaceutical Selective Cox-2 Inhibitors Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 179. Qilu Pharmaceutical Business Overview
Table 180. Qilu Pharmaceutical Recent Developments
Table 181. Taro Pharmaceuticals Selective Cox-2 Inhibitors Basic Information
Table 182. Taro Pharmaceuticals Selective Cox-2 Inhibitors Product Overview
Table 183. Taro Pharmaceuticals Selective Cox-2 Inhibitors Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 184. Taro Pharmaceuticals Business Overview
Table 185. Taro Pharmaceuticals Recent Developments
Table 186. Global Selective Cox-2 Inhibitors Sales Forecast by Region (2025-2030) & (K Units)
Table 187. Global Selective Cox-2 Inhibitors Market Size Forecast by Region (2025-2030) & (M USD)
Table 188. North America Selective Cox-2 Inhibitors Sales Forecast by Country (2025-2030) & (K Units)
Table 189. North America Selective Cox-2 Inhibitors Market Size Forecast by Country (2025-2030) & (M USD)
Table 190. Europe Selective Cox-2 Inhibitors Sales Forecast by Country (2025-2030) & (K Units)
Table 191. Europe Selective Cox-2 Inhibitors Market Size Forecast by Country (2025-2030) & (M USD)
Table 192. Asia Pacific Selective Cox-2 Inhibitors Sales Forecast by Region (2025-2030) & (K Units)
Table 193. Asia Pacific Selective Cox-2 Inhibitors Market Size Forecast by Region (2025-2030) & (M USD)
Table 194. South America Selective Cox-2 Inhibitors Sales Forecast by Country (2025-2030) & (K Units)
Table 195. South America Selective Cox-2 Inhibitors Market Size Forecast by Country (2025-2030) & (M USD)
Table 196. Middle East and Africa Selective Cox-2 Inhibitors Consumption Forecast by Country (2025-2030) & (Units)
Table 197. Middle East and Africa Selective Cox-2 Inhibitors Market Size Forecast by Country (2025-2030) & (M USD)
Table 198. Global Selective Cox-2 Inhibitors Sales Forecast by Type (2025-2030) & (K Units)
Table 199. Global Selective Cox-2 Inhibitors Market Size Forecast by Type (2025-2030) & (M USD)
Table 200. Global Selective Cox-2 Inhibitors Price Forecast by Type (2025-2030) & (USD/Unit)
Table 201. Global Selective Cox-2 Inhibitors Sales (K Units) Forecast by Application (2025-2030)
Table 202. Global Selective Cox-2 Inhibitors Market Size Forecast by Application (2025-2030) & (M USD)
List of Figures
Figure 1. Product Picture of Selective Cox-2 Inhibitors
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Selective Cox-2 Inhibitors Market Size (M USD), 2019-2030
Figure 5. Global Selective Cox-2 Inhibitors Market Size (M USD) (2019-2030)
Figure 6. Global Selective Cox-2 Inhibitors Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Selective Cox-2 Inhibitors Market Size by Country (M USD)
Figure 11. Selective Cox-2 Inhibitors Sales Share by Manufacturers in 2023
Figure 12. Global Selective Cox-2 Inhibitors Revenue Share by Manufacturers in 2023
Figure 13. Selective Cox-2 Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Selective Cox-2 Inhibitors Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Selective Cox-2 Inhibitors Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Selective Cox-2 Inhibitors Market Share by Type
Figure 18. Sales Market Share of Selective Cox-2 Inhibitors by Type (2019-2024)
Figure 19. Sales Market Share of Selective Cox-2 Inhibitors by Type in 2023
Figure 20. Market Size Share of Selective Cox-2 Inhibitors by Type (2019-2024)
Figure 21. Market Size Market Share of Selective Cox-2 Inhibitors by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Selective Cox-2 Inhibitors Market Share by Application
Figure 24. Global Selective Cox-2 Inhibitors Sales Market Share by Application (2019-2024)
Figure 25. Global Selective Cox-2 Inhibitors Sales Market Share by Application in 2023
Figure 26. Global Selective Cox-2 Inhibitors Market Share by Application (2019-2024)
Figure 27. Global Selective Cox-2 Inhibitors Market Share by Application in 2023
Figure 28. Global Selective Cox-2 Inhibitors Sales Growth Rate by Application (2019-2024)
Figure 29. Global Selective Cox-2 Inhibitors Sales Market Share by Region (2019-2024)
Figure 30. North America Selective Cox-2 Inhibitors Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Selective Cox-2 Inhibitors Sales Market Share by Country in 2023
Figure 32. U.S. Selective Cox-2 Inhibitors Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Selective Cox-2 Inhibitors Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Selective Cox-2 Inhibitors Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Selective Cox-2 Inhibitors Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Selective Cox-2 Inhibitors Sales Market Share by Country in 2023
Figure 37. Germany Selective Cox-2 Inhibitors Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Selective Cox-2 Inhibitors Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Selective Cox-2 Inhibitors Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Selective Cox-2 Inhibitors Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Selective Cox-2 Inhibitors Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Selective Cox-2 Inhibitors Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Selective Cox-2 Inhibitors Sales Market Share by Region in 2023
Figure 44. China Selective Cox-2 Inhibitors Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Selective Cox-2 Inhibitors Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Selective Cox-2 Inhibitors Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Selective Cox-2 Inhibitors Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Selective Cox-2 Inhibitors Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Selective Cox-2 Inhibitors Sales and Growth Rate (K Units)
Figure 50. South America Selective Cox-2 Inhibitors Sales Market Share by Country in 2023
Figure 51. Brazil Selective Cox-2 Inhibitors Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Selective Cox-2 Inhibitors Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Selective Cox-2 Inhibitors Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Selective Cox-2 Inhibitors Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Selective Cox-2 Inhibitors Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Selective Cox-2 Inhibitors Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Selective Cox-2 Inhibitors Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Selective Cox-2 Inhibitors Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Selective Cox-2 Inhibitors Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Selective Cox-2 Inhibitors Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Selective Cox-2 Inhibitors Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Selective Cox-2 Inhibitors Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Selective Cox-2 Inhibitors Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Selective Cox-2 Inhibitors Market Share Forecast by Type (2025-2030)
Figure 65. Global Selective Cox-2 Inhibitors Sales Forecast by Application (2025-2030)
Figure 66. Global Selective Cox-2 Inhibitors Market Share Forecast by Application (2025-2030)
